Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematol...
November 24 2020 - 8:00AM
Business Wire
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) today
announced that it will host a virtual Key Opinion Leader (KOL)
event on Monday, December 7 at 7 pm ET highlighting the latest data
from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) of
ciltacabtagene autoleucel (cilta-cel), an investigational
BCMA-directed CAR-T cell therapy being studied for the treatment of
patients with relapsed or refractory multiple myeloma. This will
follow the oral presentation of the study results (Abstract #177)
at the 2020 ASH Annual Meeting.
Intended for investors and other interested audiences, the event
includes presentations by Ying Huang, PhD, CEO and CFO of Legend
Biotech, along with the following leading professionals in
hematology and oncology:
- Sundar Jagannath, MD, Professor of Medicine, Hematology and
Medical Oncology, Mount Sinai School of Medicine; Director,
Multiple Myeloma Program at Mount Sinai Hospital.
- Thomas G. Martin, MD, Clinical Professor of Medicine, Adult
Leukemia and Bone Marrow Transplantation Program, and Associate
Director, Myeloma Program, UCSF; Co-Leader, Hematopoietic
Malignancies Program, Helen Diller Family Comprehensive Cancer
Center.
To register and to view the live webcast, please visit:
LegendBiotechASH2020.Convene.com.
About CARTITUDE-1
Cilta-cel is currently being investigated in the Phase 1b/2
CARTITUDE-1 (MMY2001, NCT03548207) registration study conducted in
the US and Japan for the treatment of patients with multiple
myeloma who have received at least 3 prior lines of therapy or are
double refractory to a PI and IMiD®, received a PI, an IMiD, and
anti-CD38 antibody and documented disease progression within 12
months of starting the most recent therapy.
About Cilta-cel
Cilta-cel is an investigational chimeric antigen receptor T
(CAR-T) cell therapy, formerly identified as JNJ-4528 in the U.S.
and Europe and LCAR-B38M in China, that is being studied in a
comprehensive clinical development program for the treatment of
patients with relapsed or refractory multiple myeloma and in
earlier lines of treatment. The design consists of a structurally
differentiated CAR-T with two BCMA-targeting single domain
antibodies. In December 2017, Legend Biotech, Inc. entered into an
exclusive worldwide license and collaboration agreement with
Janssen Biotech, Inc. (Janssen) to develop and commercialize
cilta-cel. In addition to a Breakthrough Therapy Designation (BTD)
granted in the U.S. in December 2019, cilta-cel received a PRIority
MEdicines (PRiME) designation from the European Commission in April
2019 and BTD in China in August 2020. In addition, Orphan Drug
Designation was granted for cilta-cel by the U.S. FDA in February
2019, and by the European Commission in February 2020.
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical
company engaged in the discovery and development of novel cell
therapies for oncology and other indications. Our team of over 800
employees across the United States, China and Europe, along with
our differentiated technology, global development, and
manufacturing strategies and expertise, provide us with the strong
potential to discover, develop, and manufacture cutting-edge cell
therapies for patients in need. We are engaged in a strategic
collaboration to develop and commercialize our lead product
candidate, ciltacabtagene autoleucel, an investigational BCMA
targeted CAR-T cell therapy for patients with multiple myeloma.
This candidate is currently being studied in registrational
clinical trials. To learn more about Legend Biotech, visit us on
LinkedIn, or on Twitter @LegendBiotech or at
www.legendbiotech.com.
Cautions Concerning Forward-Looking Statements
This information constitutes forward-looking statements relating
to the business of Legend, including express or implied discussions
regarding the clinical development of its product candidates and
potential attributes and benefits of such product candidates. Such
forward-looking statements reflect the current views of Legend’s
management regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from any future results,
performance or achievements expressed or implied by such
statements. In particular, Legend’s expectations could be affected
by, among other things, uncertainties involved in the development
of new pharmaceutical products; unexpected clinical trial results,
including additional analysis of existing clinical data or
unexpected new clinical data; unexpected regulatory actions or
delays or government regulation generally; Legend’s ability to
obtain or maintain patent or other proprietary intellectual
property protection; competition in general; government, industry,
and general public pricing and other political pressures. Should
one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those described herein as anticipated, believed,
estimated or expected.
The safety and efficacy of the product candidates and/or uses
under investigation have not been established. There is no
guarantee that the product candidates will receive health authority
approval or become commercially available in any country for the
uses being investigated.
The information in this press release speaks only as of the date
hereof. Legend assumes no duty to update the information to reflect
subsequent developments. Readers should not rely upon the
information on this page as current or accurate after its
publication date.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201124005327/en/
For Media and Investor Relations inquiries, please
contact: Jessie Yeung, Head of Corporate Finance and Investor
Relations, Legend Biotech jessie.yeung@legendbiotech.com or
investor@legendbiotech.com
Surabhi Verma, Manager of Investor Relations and Corporate
Communications, Legend Biotech Surabhi.verma@legendbiotech.com or
media@legendbiotech.com
For Medical Affairs inquiries, please contact: Tonia
Nesheiwat, Executive Director, Medical Affairs, Legend Biotech
tonia.nesheiwat@legendbiotech.com or
medicalinformation@legendbiotech.com
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jul 2023 to Jul 2024